Clinical Trial Update: Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica (PROMISE) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating efficacy and safety of olokizumab in polymyalgia rheumatica is active not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polymyalgia Rheumatica

Drugs mentioned

• Olokizumab (olokizumab)

Snippet

Sponsor: R-Pharm International, LLC | Conditions: Polymyalgia Rheumatica | Phase 3 | Status: ACTIVE_NOT_RECRUITING